LYL 797
Alternative Names: LYL-797Latest Information Update: 28 Jul 2025
At a glance
- Originator Lyell Immunopharma
 - Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
 - Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity No
 
Highest Development Phases
- Discontinued Solid tumours
 
Most Recent Events
- 24 Oct 2024 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral)
 - 08 Aug 2024 Lyell Immunopharma plans a phase I trial for Multiple myeloma and Chronic lymphocytic leukemia
 - 07 Aug 2024 Lyell Immunopharma announces intention to submit IND for multiple myeloma and chronic lymphocytic leukemia in second half of 2024